drugset / Trial / NCT03476798
Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II study of rucaparib, a small molecule inhibitor poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP), being tested in combination with bevacizumab in patients with recurrent cervical or endometrial cancer. The objective of this study is to determine the proportion of these patients who survive progression-free for at least 6 months while receiving this drug combination.
Timeline
- Start
- 2018-06-29
- Primary completion
- 2020-05-12
- Completion
- 2023-09-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Rucaparib | Small molecule | 600 mg | Oral |